查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1377365

大腸癌篩檢和診斷市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按篩檢、診斷、最終用戶、地區和競爭細分

Colorectal Cancer Screening and Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Screening, by Diagnostic, by End User, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球大腸癌篩檢和診斷市場價值為 94.7 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為5.20%。結直腸癌，也稱為結腸癌或直腸癌，是一種始於大腸（結腸）或直腸內壁細胞的癌症類型。它是全世界最常見的癌症類型之一。大腸直腸癌的確切原因並不總是清楚，但它通常始於結腸或直腸內壁的良性生長，稱為息肉。隨著時間的推移，其中一些息肉可能會癌變。大腸直腸癌通常是透過一系列導致細胞生長不受控制的基因突變而形成的。全球大腸直腸癌發生率上升是一個重要的促進因素。隨著這種疾病變得越來越普遍，越來越需要篩檢和診斷工具來在早期階段檢測到它。

醫療機構和專業組織制定和推廣大腸癌篩檢指南，鼓勵個人定期接受篩檢，推動市場成長。篩檢和診斷方法的技術創新，例如改進的影像技術、基因檢測和血液生物標記檢測，為患者和醫療保健提供者提供了更準確、更方便的選擇。公共衛生運動和教育措施提高了人們對大腸直腸癌和早期檢測重要性的認知。提高認知可以提高篩檢率。世界各地許多政府都啟動了結直腸癌篩檢計劃，通常針對特定年齡層或高風險族群。這些措施帶動了市場需求。大腸直腸癌篩檢測試的健康保險覆蓋範圍鼓勵個人接受篩檢，減少了獲得篩檢的經濟障礙。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 94.7億美元
2028 年市場規模 128.6億美元
2023-2028 年CAGR 5.20%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

技術進步

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球大腸癌篩檢與診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過篩檢（糞便檢查、大腸鏡檢查和乙狀結腸鏡檢查等）
    • 透過診斷（生物標記測試、大腸鏡檢查）
    • 按最終使用者（醫院和診所、臨床實驗室等）
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區大腸直腸癌篩檢與診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過篩選
    • 透過診斷
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國大腸直腸癌篩檢與診斷
    • 印度大腸癌篩檢與診斷
    • 澳洲大腸直腸癌篩檢和診斷
    • 日本大腸癌篩檢與診斷
    • 韓國大腸癌篩檢與診斷

第 7 章：歐洲大腸癌篩檢與診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過篩選
    • 透過診斷
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美大腸癌篩檢與診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過篩選
    • 透過診斷
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲大腸癌篩檢與診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過篩選
    • 透過診斷
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲結直腸癌篩檢和診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 透過篩選
    • 透過診斷
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非大腸癌篩檢與診斷
    • 沙烏地阿拉伯大腸癌篩檢與診斷
    • 阿拉伯聯合大公國大腸癌篩檢與診斷

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球造影劑代理與注射器系統市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • 臨床基因組技術有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 丹納赫公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 迪亞卡塔公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 英研化學有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 表觀基因組學公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 弗里諾姆控股公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 衛士健康公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 富士膠片控股公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 諾維吉尼克斯公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • QuidelOrtho公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 奧林巴斯公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 樂普醫療科技（北京）有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis

第 17 章：策略建議

關於我們及免責聲明

簡介目錄
Product Code: 16767

Global Colorectal Cancer Screening and Diagnostic Market has valued at USD 9.47 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.20% through 2028. Colorectal cancer, also known as colon cancer or rectal cancer, is a type of cancer that begins in the cells lining the large intestine (colon) or the rectum. It is one of the most common types of cancer worldwide. The exact cause of colorectal cancer is not always clear, but it often begins as benign growths called polyps in the inner lining of the colon or rectum. Over time, some of these polyps can become cancerous. Colorectal cancer typically develops through a series of genetic mutations that lead to uncontrolled cell growth. The rising incidence of colorectal cancer globally is a significant driver. As the disease becomes more prevalent, there is a greater need for screening and diagnostic tools to detect it in its early stages.

The establishment and promotion of colorectal cancer screening guidelines by healthcare authorities and professional organizations encourage individuals to undergo regular screening, driving market growth. Technological innovations in screening and diagnostic methods, such as improved imaging techniques, genetic testing, and blood-based biomarker assays, provide more accurate and convenient options for patients and healthcare providers. Public health campaigns and educational initiatives have raised awareness about colorectal cancer and the importance of early detection. Increased awareness can lead to higher screening rates. Many governments worldwide have launched colorectal cancer screening programs, often targeting specific age groups or high-risk populations. These initiatives drive market demand. The availability of health insurance coverage for colorectal cancer screening tests encourages individuals to undergo screening, reducing the financial barrier to access.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 9.47 Billion
Market Size 2028USD 12.86 Billion
CAGR 2023-20285.20%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Advancements in Technology

High-definition (HD) colonoscopy uses advanced imaging technology to provide clearer and more detailed images of the colon. This improves the detection of precancerous polyps and early-stage colorectal cancer during colonoscopy procedures. CT colonography is a non-invasive imaging technique that uses computed tomography (CT) scans to create three-dimensional images of the colon. It offers an alternative to traditional colonoscopy and is less invasive, making it more patient-friendly. Magnification endoscopy involves using specialized endoscopes that can magnify the colon's surface. This technology helps healthcare providers get a closer look at suspicious areas and enhances the detection of abnormalities. Narrow Band Imaging (NBI) is an endoscopic technology that uses specific wavelengths of light to enhance the visualization of blood vessels and surface structures in the colon. It aids in the detection of abnormalities that may not be visible with standard white light. Chromoendoscopy involves applying contrast agents or dyes to the colon's surface during endoscopy. This highlights abnormal tissue and improves the detection of precancerous lesions. AI and machine learning algorithms are being developed to assist healthcare providers in analyzing colonoscopy and imaging data. These algorithms can help identify and characterize polyps and lesions, reducing the risk of missed diagnoses. Research is ongoing in the development of blood-based tests that detect specific biomarkers associated with colorectal cancer. These tests aim to provide a non-invasive and convenient screening option.

Stool-based tests like fecal immunochemical tests (FIT) and DNA stool tests have evolved with improved sensitivity and specificity. They detect blood or genetic mutations associated with colorectal cancer in stool samples. Advances in molecular diagnostics have led to the identification of genetic and molecular markers associated with colorectal cancer. These markers can be used for early detection and personalized treatment strategies. Liquid biopsies involve analyzing blood or other bodily fluids for circulating tumor DNA (ctDNA) or other biomarkers. They have the potential to detect colorectal cancer and monitor treatment response. Telemedicine allows for remote consultations and discussions of colorectal cancer screening and diagnostic results. Telepathology enables pathologists to review tissue samples remotely, improving access to expertise. 3D printing technology has been used to create anatomical models of the colon and rectum, aiding in surgical planning and education for both patients and healthcare providers. Mobile apps and digital platforms are being developed to educate patients about colorectal cancer, remind them of screening appointments, and provide post-screening support. Data analytics and EHRs help healthcare providers track and manage patient screening histories, identify high-risk individuals, and improve overall healthcare management. This factor will help in the development of Global Colorectal Cancer Screening and Diagnostic Market.

Increasing Colorectal Cancer Incidence

Colorectal cancer is more common in older individuals, and as the population ages, there is a natural increase in the number of cases. The risk of developing colorectal cancer increases significantly after the age of 50. Demographic shifts, including population growth and changes in age distribution, can lead to a higher overall number of cancer cases, including colorectal cancer. Unhealthy lifestyle choices, such as diets high in processed foods, red meat, and low in fiber, along with sedentary behavior, obesity, and smoking, can increase the risk of colorectal cancer. Diets that are low in fruits, vegetables, and whole grains, which are rich in fiber and protective against colorectal cancer, contribute to the increasing incidence. The rise in obesity rates, particularly in developed countries, is associated with an increased risk of colorectal cancer. Lack of physical activity and sedentary behaviors are linked to an elevated risk of colorectal cancer. Excessive alcohol consumption is a known risk factor for colorectal cancer, and increased alcohol intake in some populations contributes to the rising incidence. Environmental factors, including exposure to certain toxins and pollutants, can contribute to an increased cancer risk. While most colorectal cancer cases are sporadic, there is a hereditary component to some cases. Genetic factors, family history, and certain inherited conditions can increase susceptibility. Despite the availability of effective screening methods, not all eligible individuals undergo regular colorectal cancer screening. This can lead to late-stage diagnoses and an increase in cases. Disparities in access to healthcare services, particularly in underserved communities or regions with limited healthcare infrastructure, can result in delayed diagnosis and treatment. In some cases, increased awareness and early detection efforts may lead to the identification of previously undiagnosed cases. This factor will pace up the demand of Global Colorectal Cancer Screening and Diagnostic Market.

Rising Awareness Campaigns

wareness campaigns provide essential information about colorectal cancer, including its risk factors, symptoms, and the value of early detection. Educated individuals are more likely to seek out screening options. These campaigns help dispel common myths and misconceptions about colorectal cancer, reducing fear and stigma associated with the disease. This, in turn, encourages more people to consider screening. Awareness campaigns often emphasize the importance of adhering to recommended screening guidelines. This helps individuals understand when they should start screening and which methods are suitable for them. Campaigns inform individuals about the various colorectal cancer screening methods available, such as colonoscopy, stool-based tests, and virtual colonoscopy. This information allows people to make informed choices based on their preferences and risk factors. Campaigns encourage individuals to discuss colorectal cancer screening with their healthcare providers. Open dialogues with healthcare professionals can lead to informed decisions about screening. By raising awareness about the importance of screening, these campaigns aim to boost screening rates, especially among those who may not have previously considered it. Awareness campaigns often target high-risk populations, such as those with a family history of colorectal cancer or specific genetic factors. By reaching these groups, campaigns can drive more targeted screening efforts.

Early detection of colorectal cancer is associated with better treatment outcomes. Awareness campaigns emphasize the benefits of catching the disease at an early, more treatable stage. Some individuals may face barriers to colorectal cancer screening, such as cost or lack of access to healthcare facilities. Awareness campaigns often address these barriers and provide information about available resources and assistance programs. By providing information and resources, awareness campaigns empower individuals to take control of their health and make informed decisions about their colorectal cancer screening and diagnostic needs. Awareness campaigns also provide support and resources for colorectal cancer survivors, helping them navigate post-treatment care and monitoring. Some awareness campaigns engage in advocacy efforts to promote policies that improve access to screening and reduce barriers. Awareness campaigns can have a global impact, raising awareness about colorectal cancer in regions where screening rates are low and encouraging governments and healthcare systems to invest in screening programs. This factor will accelerate the demand of Global Colorectal Cancer Screening and Diagnostic Market

Key Market Challenges

False Positives and Overdiagnosis

False positives occur when a screening test suggests the presence of colorectal cancer or precancerous lesions when they are not actually present. False positives can cause unnecessary anxiety and stress for patients. They often lead to additional testing and procedures, which can be invasive and carry their own risks. False positives can result in increased healthcare costs due to follow-up tests and procedures. This can strain healthcare resources and increase the financial burden on individuals and healthcare systems. Experiencing a false positive result can deter individuals from participating in future screening, as they may be apprehensive about undergoing another potentially stressful experience. Overdiagnosis occurs when a screening test detects a condition that, if left untreated, would not have progressed to clinical significance, or caused harm during the patient's lifetime. Overdiagnosis can lead to unnecessary treatment, including surgery, chemotherapy, or radiation therapy. These interventions can have physical and psychological side effects. Treating cases that would not have caused harm can lead to overtreatment, which poses risks to the patient's overall health and quality of life. Overdiagnosis and overtreatment contribute to higher healthcare costs. Resources are allocated to treating conditions that may not require intervention. Efforts are made to enhance the specificity of screening tests to reduce false positives. This includes refining the criteria for test positivity and adopting more accurate diagnostic criteria. Tailoring screening recommendations based on an individual's risk factors, such as family history and genetic predisposition, can help reduce overdiagnosis by targeting screening efforts where they are most needed.

Limited Screening Options in Developing Regions

Many developing regions lack the necessary healthcare infrastructure to support widespread colorectal cancer screening programs. This includes a shortage of healthcare facilities, trained professionals, and diagnostic equipment. Economic constraints in developing regions often limit the availability of funding for healthcare programs, including cancer screening. Screening tests, especially advanced ones, can be expensive, making them inaccessible to a large portion of the population. In many developing regions, there is a lack of awareness about colorectal cancer and the importance of screening. This leads to low demand for screening services and delays in diagnosis. Cultural beliefs and social stigmas can deter individuals from seeking colorectal cancer screening. Lack of education about the benefits of screening can also contribute to this issue. The procurement and distribution of screening tests and diagnostic equipment can be challenging in developing regions due to poor supply chain infrastructure and logistics issues. Developing regions often face a shortage of healthcare professionals, including oncologists and gastroenterologists, who can perform and interpret screening tests.

Key Market Trends

Shift Towards Non-Invasive Tests

Non-invasive tests, such as stool-based tests or blood tests, are generally more acceptable to patients because they do not involve invasive procedures like colonoscopy. This improved patient acceptance can lead to higher screening participation rates. The avoidance of invasive procedures can reduce patient discomfort and anxiety associated with colorectal cancer screening. This can encourage individuals to undergo testing. Non-invasive tests often require minimal preparation and can be performed at home, making them more convenient for patients. This convenience can lead to higher compliance with screening recommendations. Unlike colonoscopy, which typically requires sedation or anesthesia, non-invasive tests do not involve the use of these medications, eliminating the associated risks and recovery time. Non-invasive tests are generally more cost-effective compared to invasive procedures like colonoscopy, making them an attractive option for both patients and healthcare systems. Some non-invasive tests, such as stool-based tests, can be performed more frequently, allowing for regular monitoring and early detection of changes in colorectal health. Non-invasive tests can be used to reach populations with limited access to healthcare facilities or those who may be hesitant to undergo invasive procedures. Advances in non-invasive screening technologies, such as the development of highly sensitive fecal immunochemical tests (FIT), have improved their ability to detect colorectal cancer and precancerous lesions.

Segmental Insights

Screening Insights

In 2022, the Global Colorectal Cancer Screening and Diagnostic Market largest share was held by Stool-Based Test segment and is predicted to continue expanding over the coming years. Stool-based tests are non-invasive and relatively easy to administer, making them more acceptable to many individuals who may be reluctant to undergo more invasive procedures like colonoscopy. This non-invasiveness can help increase overall screening rates. Stool-based tests are generally more cost-effective compared to colonoscopy or other imaging-based methods. This affordability can make them accessible to a larger portion of the population. Collecting a stool sample can be done in the privacy of one's home, and it doesn't require dietary restrictions or bowel preparation, which is necessary for colonoscopy. This convenience encourages more people to participate in screening programs.

Diagnostics Insights

In 2022, the Global Colorectal Cancer Screening and Diagnostic Market dominated by Colonoscopy segment and is predicted to continue expanding over the coming years. Colonoscopy is considered the gold standard for colorectal cancer screening due to its high diagnostic accuracy. It allows for direct visualization of the entire colon and rectum, enabling the detection of precancerous polyps and early-stage cancers. Unlike some other screening methods, colonoscopy not only detects abnormalities but also enables the removal of precancerous polyps during the same procedure. This immediate intervention can prevent colorectal cancer from developing. Colonoscopy provides a comprehensive examination of the colon, allowing for the detection of abnormalities throughout the entire length of the colon, including the cecum, ascending colon, transverse colon, descending colon, and sigmoid colon. colonoscopy is typically recommended every 10 years for individuals at average risk of colorectal cancer, which means fewer screenings over time compared to annual or biennial stool-based tests. This makes it a convenient option for patients.

End User Insights

In 2022, the Global Colorectal Cancer Screening and Diagnostic Market largest share was dominated by Clinical Laboratories segment in the forecast period and is predicted to continue expanding over the coming years. Clinical laboratories are equipped with the necessary infrastructure and trained personnel to perform a wide range of diagnostic tests, including those related to colorectal cancer screening. They have the expertise to process and analyse samples accurately. Clinical laboratories offer a comprehensive suite of services, including various types of colorectal cancer screening tests such as fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and molecular tests. This wide range of services caters to diverse patient needs. Accredited clinical laboratories adhere to strict quality assurance standards and follow standardized protocols to ensure the accuracy and reliability of test results. This is essential for patient care and population health.

Regional Insights

The North America region dominates the Global Colorectal Cancer Screening and Diagnostic Market in 2022. North America has a relatively high prevalence of colorectal cancer, which necessitates robust screening and diagnostic efforts. Factors such as diet, lifestyle, and an aging population contribute to this prevalence. The region has well-established colorectal cancer screening guidelines issued by healthcare authorities and professional organizations. These guidelines recommend regular screening starting at a certain age (usually around 50), contributing to a high screening rate. North America boasts advanced healthcare infrastructure, including a dense network of clinical laboratories, diagnostic facilities, and healthcare providers. This infrastructure supports efficient screening and diagnosis. A substantial portion of the population in North America is covered by health insurance, which often includes coverage for colorectal cancer screening and diagnostic tests. This coverage promotes higher screening rates.

Key Market Players

Clinical Genomics Technologies Pty Ltd.

Danaher Corporation

DiaCarta, Inc.

Eiken Chemical Co., Ltd.

Epigenomics AG

Freenome Holdings, Inc.

Guardant Health, Inc.

Lepu Medical Technology (Beijing) Co., Ltd.

Novigenix SA

FUJIFILM Holdings Corporation

Olympus Corporation

QuidelOrtho Corporation

Report Scope:

In this report, the Global Colorectal Cancer Screening and Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Colorectal Cancer Screening and Diagnostic Market, By Screening:

  • Stool-Based Test
  • Fecal Occult Blood Test (FOBT) and Fecal Immunochemical Test (FIT)
  • Stool DNA Test
  • Colonoscopy and Sigmoidoscopy
  • Others

Colorectal Cancer Screening and Diagnostic Market, By Diagnostics:

  • Biomarker Test
  • Colonoscopy

Colorectal Cancer Screening and Diagnostic Market, By End User:

  • Hospitals and Clinics
  • Clinical Laboratories
  • Others

Global Colorectal Cancer Screening and Diagnostic Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Colorectal Cancer Screening and Diagnostic Market.

Available Customizations:

  • Global Colorectal Cancer Screening and Diagnostic Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Colorectal Cancer Screening and Diagnostic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Screening (Stool-Based Test, Colonoscopy and Sigmoidoscopy, others)
    • 5.2.2. By Diagnostic (Biomarker Test, Colonoscopy)
    • 5.2.3. By End User (Hospitals and Clinics, Clinical Laboratories, others)
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Colorectal Cancer Screening and Diagnostic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Screening
    • 6.2.2. By Diagnostics
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Screening
        • 6.3.1.2.2. By Diagnostics
        • 6.3.1.2.3. By End User
    • 6.3.2. India Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Screening
        • 6.3.2.2.2. By Diagnostics
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Screening
        • 6.3.3.2.2. By Diagnostics
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Screening
        • 6.3.4.2.2. By Diagnostics
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Colorectal Cancer Screening and Diagnostic Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Screening
        • 6.3.5.2.2. By Diagnostics
        • 6.3.5.2.3. By End User

7. Europe Colorectal Cancer Screening and Diagnostic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Screening
    • 7.2.2. By Diagnostics
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Screening
        • 7.3.1.2.2. By Diagnostics
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Screening
        • 7.3.2.2.2. By Diagnostics
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Screening
        • 7.3.3.2.2. By Diagnostics
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Screening
        • 7.3.4.2.2. By Diagnostics
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Colorectal Cancer Screening and Diagnostic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Screening
        • 7.3.5.2.2. By Diagnostics
        • 7.3.5.2.3. By End User

8. North America Colorectal Cancer Screening and Diagnostic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Screening
    • 8.2.2. By Diagnostics
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Screening
        • 8.3.1.2.2. By Diagnostics
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Screening
        • 8.3.2.2.2. By Diagnostics
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Colorectal Cancer Screening and Diagnostic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Screening
        • 8.3.3.2.2. By Diagnostics
        • 8.3.3.2.3. By End User

9. South America Colorectal Cancer Screening and Diagnostic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Screening
    • 9.2.2. By Diagnostics
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Colorectal Cancer Screening and Diagnostic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Screening
        • 9.3.1.2.2. By Diagnostics
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Colorectal Cancer Screening and Diagnostic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Screening
        • 9.3.2.2.2. By Diagnostics
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Colorectal Cancer Screening and Diagnostic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Screening
        • 9.3.3.2.2. By Diagnostics
        • 9.3.3.2.3. By End User

10. Middle East and Africa Colorectal Cancer Screening and Diagnostic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Screening
    • 10.2.2. By Diagnostics
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Colorectal Cancer Screening and Diagnostic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Screening
        • 10.3.1.2.2. By Diagnostics
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Colorectal Cancer Screening and Diagnostic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Screening
        • 10.3.2.2.2. By Diagnostics
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Colorectal Cancer Screening and Diagnostic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Screening
        • 10.3.3.2.2. By Diagnostics
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Contrast Media Agent and Injector System Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Clinical Genomics Technologies Pty Ltd.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Danaher Corporation
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. DiaCarta, Inc
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Eiken Chemical Co., Ltd.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Epigenomics AG
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Freenome Holdings, Inc.
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Guardant Health, Inc
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. FUJIFILM Holdings Corporation
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Novigenix SA
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. QuidelOrtho Corporation
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
  • 16.11. Olympus Corporation
    • 16.11.1. Business Overview
    • 16.11.2. Company Snapshot
    • 16.11.3. Products & Services
    • 16.11.4. Financials (In case of listed companies)
    • 16.11.5. Recent Developments
    • 16.11.6. SWOT Analysis
  • 16.12. Lepu Medical Technology (Beijing) Co., Ltd.
    • 16.12.1. Business Overview
    • 16.12.2. Company Snapshot
    • 16.12.3. Products & Services
    • 16.12.4. Financials (In case of listed companies)
    • 16.12.5. Recent Developments
    • 16.12.6. SWOT Analysis

17. Strategic Recommendations

About Us & Disclaimer